OXYGENTAPHPharmaceuticals
Oxygenta Pharmaceutical Ltd — Cash Flow Statement
₹48.38
-3.44%
Oxygenta Pharmaceutical Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | -8.79 Cr | -17.16 Cr | -11.28 Cr | -6.63 Cr | — |
| Issuance Of Capital Stock | 5.45 Cr | 28.92 Cr | 0.00 | 4.00 Cr | — |
| Capital Expenditure | -11.39 Cr | -4.11 Cr | -9.64 Cr | -4.95 Cr | — |
| End Cash Position | 0.12 Cr | 0.10 Cr | 0.11 Cr | 0.16 Cr | — |
| Other Cash Adjustment Outside Changein Cash | 1000.00 | — | — | 1.00 | -1.00 |
| Beginning Cash Position | 0.10 Cr | 0.11 Cr | 0.16 Cr | 0.45 Cr | — |
| Changes In Cash | 0.02 Cr | -54000.00 | -0.05 Cr | -0.29 Cr | — |
| Financing Cash Flow | 8.67 Cr | 17.13 Cr | 11.22 Cr | 6.33 Cr | — |
| Net Other Financing Charges | -1000.00 | 0.56 Cr | -1000.00 | -1.00 | — |
| Interest Paid Cff | -1.78 Cr | -1.59 Cr | -1.49 Cr | -0.92 Cr | — |
| Net Common Stock Issuance | 5.45 Cr | 28.92 Cr | 0.00 | 4.00 Cr | — |
| Common Stock Issuance | 5.45 Cr | 28.92 Cr | 0.00 | 4.00 Cr | — |
| Net Issuance Payments Of Debt | 5.00 Cr | -10.76 Cr | 12.71 Cr | 3.26 Cr | — |
| Net Short Term Debt Issuance | 32.48 Cr | 0.00 | — | — | — |
| Net Long Term Debt Issuance | -27.48 Cr | -10.76 Cr | 12.71 Cr | 3.26 Cr | — |
| Investing Cash Flow | -11.25 Cr | -4.09 Cr | -9.64 Cr | -4.94 Cr | — |
| Net Other Investing Changes | -1000.00 | 1000.00 | 1000.00 | — | — |
| Interest Received Cfi | 0.02 Cr | 0.02 Cr | 50000.00 | 44899.00 | — |
| Net Investment Purchase And Sale | 0.00 | 0.00 | — | — | — |
| Net PPE Purchase And Sale | -11.27 Cr | -4.11 Cr | -9.64 Cr | -4.95 Cr | — |
| Sale Of PPE | 0.12 Cr | 0.00 | — | — | — |
| Purchase Of PPE | -11.39 Cr | -4.11 Cr | -9.64 Cr | -4.95 Cr | — |
| Operating Cash Flow | 2.60 Cr | -13.05 Cr | -1.63 Cr | -1.68 Cr | — |
| Taxes Refund Paid | -0.16 Cr | 0.00 | 0.00 | -0.12 Cr | — |
| Change In Working Capital | 11.83 Cr | -3.49 Cr | 6.20 Cr | -3.58 Cr | — |
| Change In Other Current Liabilities | 12.61 Cr | -0.80 Cr | 0.54 Cr | -0.36 Cr | — |
| Change In Other Current Assets | -2.02 Cr | 0.06 Cr | -2.51 Cr | 1.07 Cr | — |
| Change In Payable | 6.91 Cr | -3.96 Cr | 21.21 Cr | -9.09 Cr | — |
| Change In Inventory | -6.80 Cr | -2.01 Cr | -4.42 Cr | 4.83 Cr | — |
| Change In Receivables | 1.18 Cr | 3.20 Cr | -8.61 Cr | -0.15 Cr | — |
| Other Non Cash Items | 0.47 Cr | 1.58 Cr | 1.48 Cr | 0.92 Cr | — |
| Provisionand Write Offof Assets | 0.77 Cr | 0.00 | — | — | — |
| Depreciation And Amortization | 3.61 Cr | 2.66 Cr | 2.05 Cr | 1.59 Cr | — |
| Depreciation | 3.61 Cr | 2.66 Cr | 2.05 Cr | 1.59 Cr | — |
| Pension And Employee Benefit Expense | 0.43 Cr | 0.08 Cr | 0.00 | 0.00 | — |
| Net Foreign Currency Exchange Gain Loss | 0.00 | -0.01 Cr | 0.00 | — | — |
| Net Income From Continuing Operations | -14.35 Cr | -13.87 Cr | -11.37 Cr | -0.49 Cr | — |
| Interest Paid Cfo | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Amortization Cash Flow | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Gain Loss On Investment Securities | — | -0.01 Cr | — | — | — |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Oxygenta Pharmaceutical Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.